CMS Open Payments · Tool
Orchard Therapeutics North America vs Aimmune Therapeutics, Inc.
Side-by-side comparison of CMS Open Payments data for Program Year 2024. Select different companies below to start a new comparison.
A larger reported total is not "better" or "worse", it is a neutral fact about disclosure volume; a reported payment documents a financial relationship, not evidence of wrongdoing.
Compare Different Companies
Relationship comparison
Which recorded payment profile is more concentrated?
Orchard Therapeutics North America has the more concentrated recorded General Payments recipient profile in Program Year 2024: its recipient-distribution HHI is 1,853, versus 149 for the other company. Its single largest recorded recipient represents 28.6% of that company's General Payments recipient total.
HHI summarizes how payments are distributed across recorded recipients: higher means a less evenly distributed recipient pattern. This is a description of CMS-reported General Payments only, not a finding about conduct, prescribing, quality, or wrongdoing. Read it with the recipient count and underlying records below.
- Orchard Therapeutics North America
- HHI 1,853 · top recipient 28.6%
- Ranked #778 of 1,838 companies by HHI
- Aimmune Therapeutics, Inc.
- HHI 149 · top recipient 4.8%
- Ranked #1,627 of 1,838 companies by HHI
Payment Overview
Orchard Therapeutics North America
- Total Payments
- $2.2M
- % of Industry
- 0.0%
- Transactions
- 77
- Avg per Transaction
- $29.1K
- Recipients
- 69
- Avg per Recipient
- $32.5K
- Payment Types
- 3
- Top Payment Type
- Travel and Lodging
Aimmune Therapeutics, Inc.
- Total Payments
- $2.3M
- % of Industry
- 0.0%
- Transactions
- 32,655
- Avg per Transaction
- $70.33
- Recipients
- 32,592
- Avg per Recipient
- $70.47
- Payment Types
- 7
- Top Payment Type
- Compensation for Services Other Than Consulting
Highlighted values indicate the higher figure for each metric.
Total payments compared
Orchard Therapeutics North America vs Aimmune Therapeutics, Inc. - total reported payments in CMS Open Payments PY2024
General Payment Types Breakdown
Category shares use each company's General Payments total, not the all-tracks (General + Research + Ownership) hero figure.
Orchard Therapeutics North America
60.1%
21.6%
18.3%
Aimmune Therapeutics, Inc.
54.6%
35.6%
4.8%
2.7%
1.8%
0.6%
Top 5 General-Payment Recipients
This list uses CMS detailed General Payments records only; it excludes research and ownership/investment records, so it does not equal the all-category totals above. A reported payment documents a financial relationship, not evidence of wrongdoing; a higher total reflects reporting volume, not conduct. Verify directly at openpaymentsdata.cms.gov.
Orchard Therapeutics North America
- 1
LAURA ADANG
$4,018.76 · 18 txns
- 2
LOUIS COHEN
$3,040.00 · 1 txns
- 3
JENNIFER BRAUN
$2,359.10 · 14 txns
- 4
LISA TENNYSON EMRICK
$1,746.40 · 8 txns
- 5
SUHAG PARIKH
$1,161.57 · 8 txns
Aimmune Therapeutics, Inc.
- 1
DANIEL A MELINE
$102,004.12 · 81 txns
- 2
AKSHAY B SHAH
$91,432.47 · 51 txns
- 3
ARIN H NEWMAN
$90,215.30 · 106 txns
- 4
JONATHAN ALAN ROSENBERG
$83,661.28 · 50 txns
- 5
PAUL FEUERSTADT
$70,187.64 · 42 txns
Summary Comparison
| Metric | Orchard Therapeutics North America | Aimmune Therapeutics, Inc. |
|---|---|---|
| Total Payments | $2.2M | $2.3M |
| % of Industry Total | 0.0% | 0.0% |
| Transaction Count | 77 | 32,655 |
| Avg per Transaction | $29.1K | $70.33 |
| Recipient Count | 69 | 32,592 |
| Avg per Recipient | $32.5K | $70.47 |
| Payment Type Count | 3 | 7 |
| Top Payment Type | Travel and Lodging | Compensation for Services Other Than Consulting |
Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. All companies in the CMS Open Payments company corpus are available in the selector. Browse all companies →
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.